In clinical practice, we found some patients with multiple myeloma developed markedly increased levels of tumor necrosis factor (TNF)- α during the CRS period after anti-BCMA CAR T cell infusion. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.